TREATMENT OF PRECOCIOUS PUBERTY BY A LONG-ACTING GONADOTROPIN-RELEASING HORMONE ANALOGUE IN CHILDREN
Authors
Abstract:
The GnRH analogue has been shown to be effective in the treatment of precocious puberty when given as a daily subcutaneous injection. We studied the effectiveness of a long-acting GnRH analogue, Triptoreline, for the treatment of central precocity, by suppressing gonadotropin and estradiol secretion in three children with true precocious puberty. One month after single dose intramuscular injection of depot GnRH analog Triptoreline, our patients showed significant decreases in serum estradiol and blunting of the responses of LH and FSH to GnRH test. No adverse effects were noted during the first six to eight months of treatment.
similar resources
treatment of precocious puberty by a long-acting gonadotropin-releasing hormone analogue in children
the gnrh analogue has been shown to be effective in the treatment of precocious puberty when given as a daily subcutaneous injection. we studied the effectiveness of a long-acting gnrh analogue, triptoreline, for the treatment of central precocity, by suppressing gonadotropin and estradiol secretion in three children with true precocious puberty. one month after single dose intramuscular inject...
full textLong-acting gonadotropin-releasing hormone analogue treatment for central precocious puberty in maternal uniparental disomy chromosome 14.
Uniparental disomy (UPD) is the inheritance of a chromosome pair from one parent and is increasingly recognized as a cause of abnormal phenotypes either due to imprinted genes or, in the case of isodisomy, to homozygosity of recessive alleles. Maternal uniparental disomy for chromosome 14 (matUPD[14]) may cause a characteristic phenotype including precocious puberty. Central precocious puberty ...
full textEffect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty
OBJECTIVES To study the effect of gonadotropin-releasing hormone analogue (GnRHa) on final adult height (FAH) among Jordanian children with central precocious puberty (CPP). Methods: It is a retrospective historical cohort study. We assessed the FAH and height gain in 43 children with CPP (39 females and 4 males) who received GnRHa and 13 children with CPP (11 females and 2 males) who did not r...
full textGonadotropin releasing hormone analog treatment in children with congenital adrenal hyperplasia complicated by central precocious puberty.
OBJECTIVE Congenital adrenal hyperplasia (CAH) can be complicated by central precocious puberty (CPP) in children, which may compromise final height. We aimed to evaluate the effect of gonadotropin-releasing hormone analog (GnRHa) therapy on growth in children with CAH. DESIGN Twelve children with CAH were enrolled in a follow-up study. Eight patients underwent the GnRH stimulation test. GnRH...
full textthe side effects of gonadotropin releasing hormone analog (diphereline) in treatment of idiopathic central precocious puberty
treatment of central precocious puberty (cpp) is the administration of gnrh analogs. metabolic syndrome comprised metabolic disturbances that confer increased risk of (cvd) diabetes mellitus (dm) and cardiovascular disease. this study is a longitudinal prospective study in pediatric endocrinology clinic. 30 non-obese children with idiopathic cpp were involved. total body weight, height, blood p...
full textGonadotropin Releasing Hormone Agonist Treatment to Increase Final Stature in Children With Precocious Puberty
In the setting of central precocious puberty (CPP), the motivation for hormonal intervention is to help the child to reach a taller adult stature than she would achieve otherwise. While gonadotropin-releasing hormone analogs (GnRHa) constitute an established treatment for improving adult stature in girls presenting with CPP up to age 6 (true precocious puberty), it is not yet clear whether or n...
full textMy Resources
Journal title
volume 5 issue 3
pages 159- 161
publication date 1991-11
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023